brand logo

Am Fam Physician. 2017;96(9):566a

Incorrect dosing requirements. The article “Treating Painful Diabetic Peripheral Neuropathy: An Update” (August 1, 2016, p. 227) incorrectly identified “no dosing adjustment requirement in patients with renal impairment” as a reason to prefer pregabalin to gaba-pentin as a first-line treatment option for painful diabetic peripheral neuropathy. However, according to the prescribing information for pregabalin, dosing changes are necessary relative to the creatinine clearance. The first full sentence of the right column on page 229 of the article should have read: “Pregabalin is preferred to gabapentin as a first-line medication because of the availability of higher-quality studies on its effects, more predictable pharmacokinetics, shorter titration periods, and the option for twice-daily dosing.” The online version of the article has been corrected.

Continue Reading

More in AFP

Copyright © 2017 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.